FibroGen's research and development teams seek to identify and develop medicines for the treatment of chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis (IPF), and locally advanced pancreatic cancer (LAPC).
The Investor Relations website contains information about FibroGen, Inc.'s business for stockholders, potential investors, and financial analysts.
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2023 and provided an update on the company’s recent developments.“We look forward to reporting topline data from four pivotal phase 3 trials...
The Investor Relations website contains information about FibroGen, Inc.'s business for stockholders, potential investors, and financial analysts.
| bindingsite | binitio | bio express | Bio Plas Inc. | Bio World | bio x cell | bioabb | bioacademia | bioassay | bioassay systems | bioassay works | bioaustralis | biobasic | biocare | biocare medical | biocarta | biocat | biocatalysts | biocell | biochain | biocheck | Biochrom ...
SAN FRANCISCO,Feb. 20, 2025(GLOBE NEWSWIRE) --FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of itsChinasubsidiary to AstraZeneca for approximately$160 million. “Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxa...
FibroGen, Inc. will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET with the investment community to further detail the company’s corporate and financia...
FibroGen, Inc. (FGEN) Frequently Asked Questions People Also Follow SymbolLast PriceChange KPTIKaryopharm Therapeutics Inc. 0.62 Post. 0.62 1.13% 0.55% AKBAAkebia Therapeutics, Inc. 2.13 Post. 2.13 -0.47% -0.01% ATRAAtara Biotherapeutics, Inc. ...
publicly any forward-looking statements whether as a result of new information, future events or otherwise. The press release reporting our financial results and business update and a webcast of today’s conference call can be found on the Investors section of FibroGen’s website at www.fibro...
Image J software (available from the National Institutes of Health website) was used to count 3 fields per well. The addition of 5 μg/ml rhCTGF significantly increased adhesion of OVCAR3 (314±61.6 vs. 578±128.2 cells, p-value<2×10−6) to peritoneal tissue (FIG. 8). The ...